On the stock market since 2019, it operates in the world of health and science. It has 2 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 38% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $115K a year. A small number, but proof the product has real buyers.
A loss of $4.8M against $115K in annual sales.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 12 months, executives reported 15 sells against just 4 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, FORZ sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: FORZ is a high-risk stock — not yet profitable, and its future rides on its product catching on.